

Highlights of This Issue 6333

SPECIAL FEATURES

CCR Translations

- 6335 | **The Role of Protein Kinase CK2 in Glioblastoma Development**
Haitao Ji and Zhimin Lu
See related article, p. 6484

CCR New Strategies

- 6338 | **New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons**
Radhe Mohan, Anita Mahajan, and Bruce D. Minsky

Molecular Pathways

- 6344 | **Molecular Pathways: Protein Methyltransferases in Cancer**
Robert A. Copeland

CCR Focus

- 6352 | **On Masterpieces and Breast Cancer Research**
Susan E. Bates
- 6353 | **Progress in Breast Cancer: Overview**
Carlos L. Arteaga
- 6360 | **Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer**
Aditya Bardia and José Baselga
- 6371 | **Incorporating Genomics into Breast Cancer Clinical Trials and Care**
Adel Tabchy, Cynthia X. Ma, Ron Bose, and Matthew J. Ellis
- 6380 | **Tackling the Diversity of Triple-Negative Breast Cancer**
Nicholas C. Turner and Jorge S. Reis-Filho
- 6389 | **Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer**
Xiang H.-F. Zhang, Mario Giuliano, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne
- 6398 | **Can Immunity to Breast Cancer Eliminate Residual Micrometastases?**
Mary L. Disis and Sasha E. Stanton

- 6404 | **CNS Metastases in Breast Cancer: Old Challenge, New Frontiers**




Nancy U. Lin, Laleh Amiri-Kordestani, Diane Palmieri, David J. Liewehr, and Patricia S. Steeg

HUMAN CANCER BIOLOGY

- 6419 | **JMJD2B Promotes Epithelial-Mesenchymal Transition by Cooperating with β -Catenin and Enhances Gastric Cancer Metastasis**
Li Zhao, Wenjuan Li, Wen Zang, Zhifang Liu, Xia Xu, Han Yu, Qing Yang, and Jihui Jia
- 6430 | **Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study**
Jiping Wang, Luis G. Carvajal-Carmona, Jen-Hwa Chu, Ann G. Zaubler, APC Trial Collaborators, Michikai Kubo, Koichi Matsuda, Malcolm Dunlop, Richard S. Houlston, Oliver Sieber, Lara Lipton, Peter Gibbs, Nicholas G. Martin, Grant W. Montgomery, Joanne Young, Paul N. Baird, Mark J. Ratain, Yusuke Nakamura, Scott T. Weiss, Ian Tomlinson, and Monica M. Bertagnolli
- 6438 | **Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer**
Takeshi Iwaya, Takeo Fukagawa, Yutaka Suzuki, Yusuke Takahashi, Genta Sawada, Masahisa Ishibashi, Junji Kurashige, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Fumitaka Endo, Hirokatsu Katagiri, Kaoru Ishida, Kohei Kume, Satoshi Nishizuka, Hisae Iinuma, Go Wakabayashi, Masaki Mori, Mitsuru Sasako, and Koshi Mimori
- 6450 | **PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival**
Hazel A. Rogers, Cerys Mayne, Rebecca J. Chapman, John-Paul Kilday, Beth Coyle, and Richard G. Grundy

CANCER THERAPY: PRECLINICAL

- 6461 **Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma**
Shih-Chi Su, Xiaoxiao Hu, Patrick A. Kenney, Megan M. Merrill, Kara N. Babaian, Xiu-Ying Zhang, Tapati Maity, Shun-Fa Yang, Xin Lin, and Christopher G. Wood
- 6473 **Cidofovir: A Novel Antitumor Agent for Glioblastoma**
Piotr Hadaczek, Tomoko Ozawa, Liliana Soroceanu, Yasuyuki Yoshida, Lisa Matlaf, Eric Singer, Estefania Fiallos, C. David James, and Charles S. Cobbs
- 6484 **Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma**
Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo Kim, Markus Bredel, and ETTY N. Benveniste
See related article, p. 6335
- 6495 **A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G₂/M Phases**
 Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hiroyuki Kishimoto, Futoshi Uno, Takeshi Nagasaka, Yasuo Urata, Shunsuke Kagawa, Robert M. Hoffman, and Toshiyoshi Fujiwara
- 6506 **Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models**
Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, and Eunice S. Wang
- 6520 **The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low *Xist* Expression**
Marion A. Salvador, Julien Wicinski, Olivier Cabaud, Yves Toiron, Pascal Finetti, Emmanuelle Josselin, Hélène Lelièvre, Laurence Kraus-Berthier, Stéphane Depil, François Bertucci, Yves Collette, Daniel Birnbaum, Emmanuelle Charafe-Jauffret, and Christophe Ginestier

6532

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Tao Liu, Wei Hu, Heather J. Dalton, Hyun Jin Choi, Jie Huang, Yu Kang, Sunila Pradeep, Takahito Miyake, Jian H. Song, Yunfei Wen, Chunhua Lu, Chad V. Pecot, Justin Bottsford-Miller, Behrouz Zand, Nicholas B. Jennings, Cristina Ivan, Gary E. Gallick, Keith A. Baggerly, David G. Hangauer, Robert L. Coleman, Michael Frumovitz, and Anil K. Sood

IMAGING, DIAGNOSIS, PROGNOSIS

6544

Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer

Joo Mi Yi, Angela A. Guzzetta, Vasudev J. Bailey, Stephanie R. Downing, Leander Van Neste, Katherine B. Chiappinelli, Brian P. Keeley, Alejandro Stark, Alexander Herrera, Christopher Wolfgang, Emmanouil P. Pappou, Christine A. Iacobuzio-Donahue, Michael G. Goggins, James G. Herman, Tza-Huei Wang, Stephen B. Baylin, and Nita Ahuja

6556

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

Carmen Behrens, Luisa M. Solis, Heather Lin, Ping Yuan, Ximing Tang, Humam Kadara, Erick Riquelme, Hector Galindo, Cesar A. Moran, Neda Kalhor, Stephen G. Swisher, George R. Simon, David J. Stewart, J. Jack Lee, and Ignacio I. Wistuba

6566

End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis

Junhee Pyo, Kyung Won Kim, Heather A. Jacene, Christopher G. Sakellis, Jennifer R. Brown, and Annick D. Van den Abbeele

CANCER THERAPY: CLINICAL

6578

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)

Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, and Susan M. Blaney

**PREDICTIVE BIOMARKERS AND
PERSONALIZED MEDICINE**

6585 **Effects of Adjuvant
Chemoradiotherapy on the
Frequency and Function of
Regulatory T Cells in Patients with
Head and Neck Cancer**

Patrick J. Schuler, Malgorzata Harasymczuk,
Bastian Schilling, Zenichiro Saze,
Laura Strauss, Stephan Lang,
Jonas T. Johnson, and Theresa L. Whiteside

6597 **ECOG Phase II Trial of Graded-Dose
Peginterferon α -2b in Patients with
Metastatic Melanoma
Overexpressing Basic Fibroblast
Growth Factor (E2602)**

Ronald S. Go, Sandra J. Lee, Donghoon Shin,
Steven M. Callister, Dean A. Jobe,
Robert M. Conry, Ahmad A. Tarhini, and
John M. Kirkwood

6605 **Photodynamic Therapy with 3-(1'-
Hexyloxyethyl) Pyropheophorbide *a*
for Cancer of the Oral Cavity**



Nestor Rigual, Gal Shafirstein,
Michele T. Cooper, Heinz Baumann,
David A. Bellnier, Ulas Sunar, Erin C. Tracy,
Daniel J. Rohrbach, Gregory Wilding,
Wei Tan, Maureen Sullivan, Mihai Merzianu,
and Barbara W. Henderson

6614 **A Phase II and Biomarker Study of
Ramucirumab, a Human
Monoclonal Antibody Targeting the
VEGF Receptor-2, as First-Line
Monotherapy in Patients with
Advanced Hepatocellular Cancer**

Andrew X. Zhu, Richard S. Finn,
Mary Mulcahy, Jayne Gurtler, Weijing Sun,
Jonathan D. Schwartz, Rita P. Dalal,
Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu,
Marek Ancukiewicz, Rakesh K. Jain,
Francis W. Nugent, Dan G. Duda, and
Keith Stuart

6624 **A Comparative Analysis of
Prognostic Factor Models for
Follicular Lymphoma Based on a
Phase III Trial of CHOP–Rituximab
versus CHOP + 131 Iodine—
Tositumomab**

Oliver W. Press, Joseph M. Unger,
Lisa M. Rimsza, Jonathan W. Friedberg,
Michael LeBlanc, Myron S. Czuczman,
Mark Kaminski, Rita M. Brazier,
Catherine Spier, Ajay K. Gopal,
David G. Maloney, Bruce D. Cheson,
Shaker R. Dakhil, Thomas P. Miller, and
Richard I. Fisher

6633 **Quantification of Excision Repair
Cross-Complementing Group 1 and
Survival in p16-Negative Squamous
Cell Head and Neck Cancers**

Ranee Mehra, Fang Zhu, Dong-Hua Yang,
Kathy Q. Cai, JoEllen Weaver,
Mahendra K. Singh, Anna S. Nikonova,
Erica A. Golemis, Douglas B. Flieder,
Harry S. Cooper, Miriam Lango, John A. Ridge,
and Barbara Burtness


AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at
<http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a human U251-MG glioblastoma cell transfected with 100 nM of non-target siRNA. Phalloidin (green) and DAPI (blue) staining shows organized F-actin and cell morphology. For details, see the article by Zheng and colleagues on page 6484 of this issue.



Clinical Cancer Research

19 (23)

Clin Cancer Res 2013;19:6333-6643.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.